IVCC is delighted to take part in the upcoming Annual Conference of the Pan African Mosquito Association (PAMCA) in Kigali, Rwanda from the 26th to 28th September. With a focus on harnessing local institutional & community support for the elimination of vector-borne diseases (VBDs), this year’s conference will be thought-provoking and stimulating.
To find out about the work of IVCC, it’s partnerships and its pipeline of innovative vector control solutions, visit the IVCC booth throughout the conference.
IVCC will also contribute to several Parallel Symposiums, Parallel Scientific Sessions, and Turbo Talks, presenting updates about specific projects and initiatives. IVCC project partners will showcase the latest developments in three large epidemiological studies for Attractive Targeted Sugar Baits (ATSB ®) at the Monday 26th (15:30-17:00*) turbo talks and at the Parallel Symposium 6: Presenting the ATSB® (Attractive Targeted Sugar Bait); a novel outdoor intervention (Wednesday 28th, 14:00 to 15:30).
Indoor residual spraying (IRS) is another important topic at PAMCA 2022. IVCC team members Graham Small and Janneke Snetselaar will present results on the bioefficacy of VECTRON™ T500 in laboratory, experimental hut and community trials during Parallel Symposium 3: Supporting improved insect resistance management strategies – a new mode of action for Indoor Residual Spray (IRS) programmes (Monday 26th September, 14:00 to 15:30.
Led by IVCC, the New Nets Project (NNP) is piloting new tools to strengthen the insecticide-treated net (ITN) market. At PAMCA, NNP Partners will present results of field trials, including access, use, barriers to use, entomological findings, bio-efficacy, and durability studies of the dual insecticide nets in Mozambique, Rwanda and Tanzania. There are poster presentations daily, as well as an oral presentation. Visit the conference programme for full details.
Find out more about 8th PAMCA Annual Conference and Exhibition online, including the full conference programme, details about keynote speakers, the event’s sponsors and exhibitors.
*all times shown are given in Central Africa Time, the local time zone (Rwanda is GMT+2h).
Interceptor® G2 (IG2), a new dual-insecticide bed net, proves effective at preventing malaria during trials 26th August 2022
Interceptor® G2 (IG2), a new dual-insecticide bed net, owned by BASF and supported by the IVCC, has been shown to be impressively effective at preventing malaria during trials. Helen Jamet, Deputy Director of Vector Control at the Bill & Melinda Gate Foundation, co-funders of the project, writes about how the Interceptor® G2 nets provide a novel way to target mosquitos. Read more here.
Image credit: PSI.
ATSB®- discovering a potential new outdoor biting invention tool 26th August 2022To celebrate World Mosquito Day, the Bill & Melinda Gates Foundation have produced a short information video about a potential new outdoor biting invention tool called Attractive Targeted Sugar Bait (ATSB®) which is being developed by Westham with support from IVCC as its funding partners including the Foundation. Watch the video below.
MMV and IVCC make 240 compounds available to stimulate research into new drugs and insecticides 22nd August 2022
On World Mosquito Day (Saturday 20th August), MMV and the Innovative Vector Control Consortium (IVCC) launched the Global Health Priority Box to provide scientists with free access to a collection of compounds with confirmed activity against infectious and mosquito-borne diseases, and vectors of global concern.
Download the press release to read the full story.
Implementing IRM by rotating IRS products with different modes of action 27th September 2022Indoor residual spraying (IRS) has historically been a powerful malaria vector control intervention. IRS can quickly reduce malaria transmission by reducing adult mosquito vector density and longevity.
The efficacy of IRS for malaria control is threatened by widespread resistance in Anopheline vectors to the limited number of insecticide classes currently approved for public health use. Pyrethroid resistance is present across Africa and resistance to carbamates and organophosphates, which were for many years the only alternative IRS insecticide classes to pyrethroids, is also increasing in Anopheles vector populations. In response to the growing threat of resistance to the efficacy of IRS, the World Health Organization’s (WHO) Global Plan for Insecticide Resistance Management (GPIRM) in Malaria has recommended the use of IRS products containing insecticides with different modes of action in annual rotations.
The use of rotations for IRM relies on the fitness cost that resistance mechanisms have on mosquitoes. Removing selection pressure exerted by a particular insecticide by switching to alternative insecticide classes will result in the frequency of resistance declining over time. Therefore, IRM based on the rotation of different IRS products will reduce selection pressure for the maintenance of existing insecticide resistance and reduce the speed of development of further resistance. However, implementation of IRS product rotations requires at least three IRS insecticides with different modes of action. This is driving the development of a more diverse portfolio of IRS formulations containing new chemistries which can provide sustained control of insecticide-resistant malaria vector populations.
Broflanilide (TENEBENAL™) is a novel insecticide discovered by Mitsui Chemicals Agro, Inc. (MCAG) which has been formulated as VECTRON™ T500, a wettable powder for IRS. Broflanilide is a meta-diamide insecticide which acts as a non-competitive antagonist of the γ -aminobutyric acid (GABA) receptor of chloride channels of the insect inhibitory nervous system and has been classified by the Insecticide Resistance Action Committee (IRAC) as a GABA-gated chloride channel allosteric modulator (IRAC Group 30). In a collaborative project between MCAG and IVCC, supported by a network of collaborating trials facilities in Africa, the bioefficacy of VECTRON™ T500 has been evaluated in laboratory, experimental hut and community trials. VECTRON™ T500 has demonstrated excellent activity against pyrethroid-resistant strains and populations of Anopheles with residual efficacy of 6 months or more on various wall substrates. These results indicate the potential of VECTRON™ T500 as an addition to the arsenal of IRS products needed to maintain both control of malaria and IRM of malaria-transmitting mosquitoes.
Indoor residual spraying (IRS) is an important topic at this week’s Pan-Africa Mosquito Control Association (PAMCA) Conference, in Rwanda. IVCC team members Graham Small and Janneke Snetselaar will present results on the bioefficacy of VECTRON™ T500 in laboratory, experimental hut and community trials during Parallel Symposium 3: Supporting improved insect resistance management strategies – a new mode of action for Indoor Residual Spray (IRS) programmes (Monday 26th September, 14:00 to 15:30 (GMT+2).